Neutrophils and TRAIL: Insights into BCG immunotherapy for bladder cancer

Mark P. Simons, William M. Nauseef, Thomas S. Griffith*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

38 Scopus citations


Bladder cancer is a huge economic burden on the healthcare system and is responsible for approximately 5% of all cancer deaths in humans. Mycobacterium bovis BCG-based therapy is the treatment of choice for superficial bladder cancer. Bacillus Calmette-Guerin (BCG) instillation in the bladder results in a massive local inflammatory response that has secondary antitumor properties. Recent studies have demonstrated that neutrophils present in the bladder after BCG instillation release large amounts of the apoptosis-inducing molecule TRAIL, as well as chemokines that recruit other immune cells, suggesting that neutrophils play a key role in the antitumor response to BCG therapy. This review discusses the impact of these findings on the understanding of the antitumor mechanisms underlying BCG-based immunotherapy for bladder cancer.

Original languageEnglish
Pages (from-to)79-93
Number of pages15
JournalImmunologic Research
Issue number1-3
StatePublished - Nov 2007


  • BCG
  • Mycobacterium
  • Neutrophil
  • PMN


Dive into the research topics of 'Neutrophils and TRAIL: Insights into BCG immunotherapy for bladder cancer'. Together they form a unique fingerprint.

Cite this